Results of the Prodige 2-ACCORD 12/0405 Randomized trial comparing two neoadjuvant chemo-radiotherapy (Cape 45 vs Capox 50) in patients with T3-4 rectal cancer.
Jean-Pierre GERARD, D. Azria, S. Gourgou-Bourgade, I. Martel-Laffay, C. Hennequin, P.L. Etienne, V. Vendrely, T. Conroy, E. François, C. Montoto-Grillot, for the FNCLCC - FFCD
编辑: ludongcn 作者:丁香园通讯员
以下网友留言只代表网友个人观点，不代表网站观点
